MX2018010334A - Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak). - Google Patents
Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak).Info
- Publication number
- MX2018010334A MX2018010334A MX2018010334A MX2018010334A MX2018010334A MX 2018010334 A MX2018010334 A MX 2018010334A MX 2018010334 A MX2018010334 A MX 2018010334A MX 2018010334 A MX2018010334 A MX 2018010334A MX 2018010334 A MX2018010334 A MX 2018010334A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- inhibiting activity
- jak
- crystal
- effect
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un objeto de la presente invención es proporcionar un compuesto con una excelente actividad inhibidora de JAK1. El compuesto de la invención tiene actividad inhibidora de JAK1, y por lo tanto, efecto inmunosupresor, efecto antiinflamatorio, efecto antiproliferativo, etc., y es útil en el tratamiento de las enfermedades, por ejemplo, artritis reumatoide, enfermedad inflamatoria intestinal, psoriasis, vasculitis, asma bronquial, enfermedad pulmonar obstructiva crónica, sinusitis eosinofílica y pólipo nasal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016039315 | 2016-03-01 | ||
| PCT/JP2017/007594 WO2017150477A1 (ja) | 2016-03-01 | 2017-02-28 | Ｊａｋ阻害作用を有する化合物の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018010334A true MX2018010334A (es) | 2018-11-09 |
Family
ID=59743962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010334A MX2018010334A (es) | 2016-03-01 | 2017-02-28 | Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak). |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10822350B2 (es) |
| EP (1) | EP3424930B1 (es) |
| JP (1) | JP6791239B2 (es) |
| KR (1) | KR102653231B1 (es) |
| CN (1) | CN108699082B (es) |
| BR (1) | BR112018016523B1 (es) |
| CA (2) | CA3015464C (es) |
| CY (1) | CY1123607T1 (es) |
| DK (1) | DK3424930T3 (es) |
| ES (1) | ES2844978T3 (es) |
| HR (1) | HRP20210062T1 (es) |
| HU (1) | HUE051615T2 (es) |
| LT (1) | LT3424930T (es) |
| MX (1) | MX2018010334A (es) |
| PL (1) | PL3424930T3 (es) |
| PT (1) | PT3424930T (es) |
| RS (1) | RS61238B1 (es) |
| RU (1) | RU2705721C1 (es) |
| SI (1) | SI3424930T1 (es) |
| TW (1) | TWI712604B (es) |
| WO (1) | WO2017150477A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI712604B (zh) * | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
| AU2021339955A1 (en) * | 2020-09-14 | 2023-04-06 | Eurochem Antwerpen | N-heterocyclic compounds used as nitrification inhibitor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3600390A1 (de) | 1986-01-09 | 1987-07-16 | Hoechst Ag | Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel |
| GB2432834A (en) | 2004-01-12 | 2007-06-06 | Cytopia Res Pty Ltd | Selective Kinase Inhibitors |
| ZA200802685B (en) * | 2005-09-30 | 2009-10-28 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| NZ569899A (en) | 2006-01-17 | 2011-06-30 | Vertex Pharma | Azaindoles useful as inhibitors of janus kinases |
| KR20120108042A (ko) | 2008-03-11 | 2012-10-04 | 인사이트 코포레이션 | Ｊａｋ 억제제로서의 아제티딘 및 시클로부탄 유도체 |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| JP5490137B2 (ja) * | 2008-12-19 | 2014-05-14 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | プロテインキナーゼ阻害薬としての二環式ピラゾール |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JP5739446B2 (ja) | 2009-12-18 | 2015-06-24 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジン化合物 |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
| CA2781578A1 (en) | 2010-01-12 | 2011-07-21 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| WO2012022045A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| WO2012037132A1 (en) | 2010-09-14 | 2012-03-22 | Exelixis, Inc. | Phtalazine derivatives as jak1 inhibitors |
| WO2012054364A2 (en) | 2010-10-22 | 2012-04-26 | Merck Sharp & Dohme Corp. | Bicyclic diamines as janus kinase inhibitors |
| WO2012085176A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors |
| WO2013025628A1 (en) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
| TWI712604B (zh) * | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
-
2017
- 2017-02-08 TW TW106104074A patent/TWI712604B/zh active
- 2017-02-28 DK DK17759943.8T patent/DK3424930T3/da active
- 2017-02-28 KR KR1020187027122A patent/KR102653231B1/ko active IP Right Grant
- 2017-02-28 HU HUE17759943A patent/HUE051615T2/hu unknown
- 2017-02-28 SI SI201730521T patent/SI3424930T1/sl unknown
- 2017-02-28 RU RU2018134041A patent/RU2705721C1/ru active
- 2017-02-28 CA CA3015464A patent/CA3015464C/en active Active
- 2017-02-28 US US16/077,889 patent/US10822350B2/en active Active
- 2017-02-28 WO PCT/JP2017/007594 patent/WO2017150477A1/ja active Application Filing
- 2017-02-28 ES ES17759943T patent/ES2844978T3/es active Active
- 2017-02-28 BR BR112018016523-9A patent/BR112018016523B1/pt active IP Right Grant
- 2017-02-28 LT LTEP17759943.8T patent/LT3424930T/lt unknown
- 2017-02-28 EP EP17759943.8A patent/EP3424930B1/en active Active
- 2017-02-28 RS RS20201509A patent/RS61238B1/sr unknown
- 2017-02-28 MX MX2018010334A patent/MX2018010334A/es unknown
- 2017-02-28 PT PT177599438T patent/PT3424930T/pt unknown
- 2017-02-28 CN CN201780014551.5A patent/CN108699082B/zh active Active
- 2017-02-28 PL PL17759943T patent/PL3424930T3/pl unknown
- 2017-02-28 JP JP2018503309A patent/JP6791239B2/ja active Active
- 2017-02-28 CA CA3206830A patent/CA3206830A1/en active Pending
-
2020
- 2020-09-29 US US17/035,947 patent/US11377453B2/en active Active
- 2020-12-02 CY CY20201101142T patent/CY1123607T1/el unknown
-
2021
- 2021-01-13 HR HRP20210062TT patent/HRP20210062T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210017191A1 (en) | 2021-01-21 |
| WO2017150477A1 (ja) | 2017-09-08 |
| BR112018016523A2 (pt) | 2018-12-26 |
| CA3015464C (en) | 2024-04-23 |
| KR102653231B1 (ko) | 2024-04-01 |
| SI3424930T1 (sl) | 2021-01-29 |
| JP6791239B2 (ja) | 2020-11-25 |
| DK3424930T3 (da) | 2021-01-11 |
| CY1123607T1 (el) | 2022-03-24 |
| TW201731855A (zh) | 2017-09-16 |
| EP3424930A1 (en) | 2019-01-09 |
| ES2844978T3 (es) | 2021-07-23 |
| EP3424930A4 (en) | 2019-07-10 |
| CN108699082B (zh) | 2021-04-09 |
| HUE051615T2 (hu) | 2021-03-01 |
| US20190048023A1 (en) | 2019-02-14 |
| US11377453B2 (en) | 2022-07-05 |
| LT3424930T (lt) | 2021-01-11 |
| RS61238B1 (sr) | 2021-01-29 |
| CA3206830A1 (en) | 2017-09-08 |
| RU2705721C1 (ru) | 2019-11-11 |
| CA3015464A1 (en) | 2017-09-08 |
| TWI712604B (zh) | 2020-12-11 |
| CN108699082A (zh) | 2018-10-23 |
| PT3424930T (pt) | 2020-12-04 |
| US10822350B2 (en) | 2020-11-03 |
| KR20180116341A (ko) | 2018-10-24 |
| PL3424930T3 (pl) | 2021-05-04 |
| BR112018016523B1 (pt) | 2024-02-06 |
| EP3424930B1 (en) | 2020-11-04 |
| JPWO2017150477A1 (ja) | 2018-12-27 |
| HRP20210062T1 (hr) | 2021-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501713A1 (en) | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders | |
| EA201400729A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ СОДЕРЖАТ ГЛИТАЗОНЫ И Nrf2 АКТИВАТОРЫ | |
| CL2015002301A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c. | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| NZ720660A (en) | Apoptosis signal-regulating kinase inhibitors | |
| EA201491786A1 (ru) | ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1 | |
| NZ629728A (en) | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | |
| MA40076A (fr) | Inhibiteurs de syk | |
| EA201590721A1 (ru) | Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы | |
| MX2017006049A (es) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidro piridinas como inhibidores de bace1. | |
| WO2014151456A3 (en) | Treatment of inflammatory diseases | |
| CY1123320T1 (el) | Ενωση πυραζολοθειαζολης και φαρμακο που την περιλαμβανει | |
| EP3735248A4 (en) | PROCESS FOR INHIBITED OR ELIMINATING EOSINOPHILIC DISEASES OF THE RESPIRATORY TRACT AND ASSOCIATED CONDITIONS | |
| MX2018010334A (es) | Cristal de compuesto que tiene actividad inhibidora de la cinasa de janus (jak). | |
| MX2021008819A (es) | Analogos de cisteamina resistentes a la ado y sus usos. | |
| TR201905319T4 (tr) | Nevralji, ağrı, KOAH (Kronik, Obstruktif Akciğer Hastalığı) ve astım tedavisinde TRPM8-inhibitörleri olarak yararlı 2-aril-4-hidroksi-1,3-tiyazol türevleri. | |
| WO2015198217A3 (en) | Antibodies specific for il-17a fused to hyaluronan binding peptide tags | |
| MX2021015553A (es) | Inhibidores de arginasa novedosos. | |
| BR112017004163A2 (pt) | método de tratamento e composições com um inibidor de quinase pi3k delta e gamma duplo e um corticostoide | |
| EP3694521A4 (en) | TOPICAL METHOTREXATE SOLUTION FOR TREATMENT OF PSORIASIS | |
| MX2016001747A (es) | Derivados de difeniloxialquilamina y derivados de ariloxialquilamina, composicion farmaceutica, uso de dicha composicion farmaceutica para tratar, prevenir o inhibir enfermedades inflamatorias pulmonares cronicas y metodo para tratar o prevenir dichas enfermedades. | |
| UA113645C2 (xx) | ТРИАЗОЛОНИ ЯК ІНГІБІТОРИ mPGES-1 | |
| EP3261630A4 (en) | Compositions and combinations for the treatment of angiogenesis diseases and disorders | |
| EP3245215A4 (en) | Methods of treating neurological inflammatory disorders | |
| ITUB20153334A1 (it) | Giunto per il collegamento amovibile di due pannelli di mobili assemblabili ortogonali tra loro |